2023 Press Releases

Dr. Debra Saliba to deliver the Henderson State-of-the-Art Lecture at #AGS23, focusing on giving voice to frail older adults so that the care and services they receive are more targeted to their needs and goals

  • Dr. Debra Saliba (@DebraSalibaMD), Henderson State-of-the-Art Lecturer at @AmerGeriatrics’ #AGS23 annual meeting, will discuss giving voice to frail older adults http://ow.ly/7BKq50NInVv

New York, NY (April 13, 2022) — The American Geriatrics Society (AGS) celebrates Debra Saliba, MD, MPH, AGSF as recipient of the 2023 Edward Henderson Award for her lifelong focus on giving voice to frail older adults so that the care and services they receive better reflect their needs and goals. She will deliver the Society’s Henderson State-of-the-Art Lecture at the AGS 2023 Annual Scientific Meeting (#AGS23) in Long Beach, CA (May 4-6, pre-conference day May 3).

Research Presented at #AGS23 Focuses on Electronic Medical Records, Geriatric Emergency Departments, and Life Expectancy Predictions

  • At #AGS23, @AmerGeriatrics and #geriatrics experts cast a wide net for social & scientific innovations shaping better care for us all as we age. http://ow.ly/gLWj50Nt1lI

New York (March 27, 2023) – Researchers presenting at this year’s American Geriatrics Society (AGS) Annual Scientific Meeting (#AGS23) to be held May 4-6, 2023 in Long Beach, California, represent the best and brightest in geriatrics scholarship, with this year’s selection drawn from a pool of more than 1071 submissions. Highlights from this year’s prestigious AGS23 Plenary Paper Session (Thurs., May 4 9:30-10:15am) include:

When Should Electronic Medical Records Stop Reminders for Cancer Screening in Older Adults? – A National Physician Survey (presented by Nancy L. Schoenborn, MD, MHS)

AGS Congratulates New Board of Directors and Nominating Committee Members

  • Today, the AGS (@amergeriatrics) announced the results of recent AGS Board and Nominating Committee elections. See here for details: http://ow.ly/iuxL50NeIO

New York (March 10, 2023) – Today, the American Geriatrics Society (AGS) announced the results of recent AGS Board and Nominating Committee elections.

The AGS Board and Nominating Committee are comprised of geriatrics health professionals who are committed to improving the health, independence, and quality of life for all of us as we age. The following AGS Members were elected to the AGS Board of Directors by AGS members:

Mark Supiano, MD, AGSF, AGS President-Elect

Mark Supiano, MD, AGSF is the Chief of the Geriatrics Division at the University of Utah, where he also serves as the Executive Director of the university’s Center on Aging. An AGS member since 1985, Dr. Supiano has held many leadership roles within the Society, including: Program Chair of the 2006 AGS Annual Scientific Meeting, Associate Editor of the JAGS Editorial Board (2000-2005), and as a Board Member of the ADGAP Board of Directors (2007-2017), ultimately serving as both its President and Board Chair. Dr. Supiano is now concluding his third year as AGS Treasurer.   

Judith L. Beizer, PharmD, BCGP, FASCP, AGSF, AGS Board Member (2nd term)

AGS supports CMS decision to Maintain Current National Coverage Determination for Monoclonal Antibodies

  • AGS supports CMS’ decision to not reopen its NCD on monoclonal antibodies and appreciates CMS’ commitment to review any new evidence that becomes available, such as evidence of clinical benefit, that may lead CMS to reconsider the NCD. http://ow.ly/nExW50N6pS

New York (March 2, 2023) — The American Geriatrics Society (AGS) supports the decision from the Centers for Medicare and Medicaid Services (CMS) to not reconsider its prior national coverage determination (NCD) for Food and Drug Administration (FDA)-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease (AD).  We appreciate CMS’ commitment to expeditiously review any new evidence that comes available that could lead to a reconsideration and change in the NCD, such as evidence that answers the Coverage with Evidence Development (CED) questions or approval by the FDA based upon evidence of clinical benefit.

Back to Top